Cargando…

1542. MR-proADM Biomarker Predicts COVID-19 Clinical Outcomes: a US-based Cohort Study

BACKGROUND: Mid-regional proadrenomedullin (MR-proADM) is a biomarker released following endothelial damage. Our study aimed to investigate baseline MR-proADM as a predictor of a wider range of clinical outcomes of varying severity in patients admitted with COVID-19 from a US-based multicenter trial...

Descripción completa

Detalles Bibliográficos
Autor principal:	Mansour, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751617/ http://dx.doi.org/10.1093/ofid/ofac492.097

Ejemplares similares

MR-proADM as prognostic factor of outcome in COVID-19 patients
por: Sozio, Emanuela, et al.
Publicado: (2021)

MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients
por: Cameli, Paolo, et al.
Publicado: (2023)

Dataset of the associations of aldosterone to renin ratio with MR-proANP and MR-proADM
por: Then, Cornelia, et al.
Publicado: (2016)

MR-proADM and MR-proANP levels in patients with acute pulmonary embolism
por: Öner, Önsel, et al.
Publicado: (2020)

Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review
por: Önal, Uğur, et al.
Publicado: (2018)

Application of MR-ProADM to predict prevention of hospitalisation, derived from a multi-centre study
por: Cullinan, Milo, et al.
Publicado: (2019)

Role of MR-proADM in the risk stratification of COVID-19 patients assessed at the triage of the Emergency Department
por: Minieri, Marilena, et al.
Publicado: (2021)

The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections
por: Baumann, Philipp, et al.
Publicado: (2022)

Predictive Value of MR-proADM in the Risk Stratification and in the Adequate Care Setting of COVID-19 Patients Assessed at the Triage of the Emergency Department
por: Minieri, Marilena, et al.
Publicado: (2022)

Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study
por: Montrucchio, Giorgia, et al.
Publicado: (2021)

Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study
por: Gar, Christina, et al.
Publicado: (2022)

Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study
por: Vigué, Bernard, et al.
Publicado: (2016)

Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis
por: Liu, Dan, et al.
Publicado: (2016)

Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients
por: García de Guadiana-Romualdo, Luis, et al.
Publicado: (2021)

Short‐Term Influence of Radiofrequency Ablation on NT‐proBNP, MR‐proANP, Copeptin, and MR‐proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study
por: Charitakis, Emmanouil, et al.
Publicado: (2016)

Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium
por: Sujana, Chaterina, et al.
Publicado: (2022)

Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control
por: Iwao, Motoshi, et al.
Publicado: (2021)

Mid-Regional Proadrenomedullin (MR-proADM) and Microcirculation in Monitoring Organ Dysfunction of Critical Care Patients With Infection: A Prospective Observational Pilot Study
por: Domizi, Roberta, et al.
Publicado: (2021)

Response to: MR-proADM has a good ability to predict mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!
por: van Oers, Jos A.H., et al.
Publicado: (2022)

MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!
por: Honore, Patrick M., et al.
Publicado: (2022)

Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score
por: Travaglino, Francesco, et al.
Publicado: (2012)

Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study
por: Graziadio, Sara, et al.
Publicado: (2018)

MR‐proADM as a Prognostic Marker in Patients With ST‐Segment–Elevation Myocardial Infarction—DANAMI‐3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy
por: Falkentoft, Alexander C., et al.
Publicado: (2018)

The TRIAGE-ProADM Score for an Early Risk Stratification of Medical Patients in the Emergency Department - Development Based on a Multi-National, Prospective, Observational Study
por: Kutz, Alexander, et al.
Publicado: (2016)

Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients
por: Fialek, Bartosz, et al.
Publicado: (2023)

1542. Infectious Complications in Patients Following Umbilical Cord Blood Transplant (UCBT) for Hematologic Malignancy
por: Linder, Kathleen A, et al.
Publicado: (2018)

856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
por: Atallah, Johnny, et al.
Publicado: (2023)

1542. Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?
por: Lat, Allen K, et al.
Publicado: (2023)

1542 The Effect of Physical Proximity of HIV Testing Centers on HIV Testing Uptake in Northern Tanzania
por: Beamesderfer, Julia, et al.
Publicado: (2014)

1542. The Evaluation of the In Vitro Synergy of Colistin in Combination with Meropenem and Tigecycline against 50 Multi-Drug-resistant Acinetobacter baumannii strains
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

Biochemical characterization of the Helicobacter pylori bactofilin-homolog HP1542
por: Holtrup, Sven, et al.
Publicado: (2019)

1542. Provider Uptake of Extragenital Screening for Gonorrhea and Chlamydia in Active Duty Air Force Members with Incident HIV Diagnosis
por: Lamb, Christian C, et al.
Publicado: (2020)

P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
por: Birndt, Sebastian, et al.
Publicado: (2023)

Identification of Inflammation-Related Biomarker Pro-ADM for Male Patients With Gout by Comprehensive Analysis
por: Qiu, Kangli, et al.
Publicado: (2022)

To ADM or not to ADM? Outcomes of Pre-pectoral Prosthetic Reconstruction after Nipple-Sparing Mastectomy with and without Acellular Dermal Matrix
por: Bushong, E., et al.
Publicado: (2023)

Historia documental de la colonia en Tabasco, 1542-1642 : estudio de rescate paleográfico
por: García Hernández, Beatriz
Publicado: (1994)

Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China: Dong Y, Mo X, Hu Y, et al. Pediatrics. 2020; doi: 10.1542/peds.2020-0702.
por: Eastin, Carly, et al.
Publicado: (2020)

Acute exacerbations of copd (AECOPD) in the emergency room (ER): prognostic value of proadrenomedulline (PROADM)
por: Dres, M, et al.
Publicado: (2015)

Antología de documentos para la historia de la colonia en Tabasco, 1542-1642 /
Publicado: (2000)

The working point $Q_{H}$ = 15.38, $Q_{V}$ = 15.42 and single bunch acceleration
por: Boussard, D, et al.
Publicado: (1978)

Cannot write session to /tmp/vufind_sessions/sess_cggjptueiffuroiknotilb2t4c